Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedApr 09, 2026
DataAggregated Company Financials
Companies1388
  • 7D1.4%
  • 3M-6.0%
  • 1Y11.1%
  • YTD-3.7%

Over the last 7 days, the Healthcare industry has risen 1.4%, driven by gains from UnitedHealth Group of 12%. In the last 12 months, the industry was up 11%. Earnings are forecast to grow by 16% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 09 Apr 2026US$6.2tUS$3.3tUS$127.2b23.1x48.5x1.9x
Sat, 07 Mar 2026US$6.4tUS$3.3tUS$126.1b24.9x50.7x2x
Mon, 02 Feb 2026US$6.5tUS$3.2tUS$126.6b27.8x51.2x2x
Wed, 31 Dec 2025US$6.5tUS$3.2tUS$134.8b26x48.4x2x
Fri, 28 Nov 2025US$6.6tUS$3.2tUS$133.5b26.7x49.1x2.1x
Sun, 26 Oct 2025US$6.1tUS$3.1tUS$140.4b25.8x43.3x2x
Tue, 23 Sep 2025US$5.7tUS$3.1tUS$137.6b23.9x41.4x1.8x
Thu, 21 Aug 2025US$5.7tUS$3.1tUS$137.2b23.8x41.3x1.8x
Sat, 19 Jul 2025US$5.4tUS$3.0tUS$128.8b22.7x42.3x1.8x
Mon, 16 Jun 2025US$5.5tUS$3.0tUS$127.4b23.5x43.5x1.8x
Wed, 14 May 2025US$5.5tUS$3.0tUS$125.7b24.3x43.8x1.8x
Fri, 11 Apr 2025US$5.4tUS$2.6tUS$81.7b24.8x65.9x2x
Sun, 09 Mar 2025US$5.8tUS$2.6tUS$79.0b27.5x73.7x2.2x
Tue, 04 Feb 2025US$6.1tUS$2.9tUS$85.2b27.1x72x2.1x
Thu, 02 Jan 2025US$5.8tUS$2.9tUS$79.4b27.5x72.6x2x
Sat, 30 Nov 2024US$6.2tUS$2.9tUS$77.3b28.8x79.8x2.1x
Mon, 28 Oct 2024US$6.0tUS$2.8tUS$59.1b29.1x102.2x2.1x
Wed, 25 Sep 2024US$6.3tUS$2.8tUS$60.1b30.2x104x2.2x
Fri, 23 Aug 2024US$6.2tUS$2.8tUS$56.4b30.8x110.8x2.2x
Sun, 21 Jul 2024US$6.3tUS$2.8tUS$60.7b31.7x103.5x2.2x
Tue, 18 Jun 2024US$6.2tUS$2.8tUS$62.5b30.2x99x2.2x
Thu, 16 May 2024US$6.1tUS$2.8tUS$64.0b30.9x96.1x2.2x
Sat, 13 Apr 2024US$6.1tUS$2.8tUS$85.3b31.4x71.2x2.2x
Mon, 11 Mar 2024US$6.3tUS$2.8tUS$85.3b32.5x73.8x2.3x
Wed, 07 Feb 2024US$6.3tUS$2.8tUS$84.0b31.5x75.2x2.3x
Fri, 05 Jan 2024US$6.3tUS$2.8tUS$90.0b31.7x70x2.2x
Sun, 03 Dec 2023US$5.9tUS$2.8tUS$91.4b28.8x65x2.1x
Tue, 31 Oct 2023US$5.6tUS$2.8tUS$99.5b24.7x55.9x2x
Thu, 28 Sep 2023US$5.9tUS$2.8tUS$98.5b27.4x59.7x2.1x
Sat, 26 Aug 2023US$6.1tUS$2.8tUS$99.0b27.7x61.6x2.2x
Mon, 24 Jul 2023US$6.2tUS$2.7tUS$110.9b26.9x55.5x2.2x
Wed, 21 Jun 2023US$6.0tUS$2.7tUS$109.9b26.2x54.8x2.2x
Fri, 19 May 2023US$5.9tUS$2.7tUS$110.8b24.2x53.6x2.2x
Sun, 16 Apr 2023US$6.0tUS$2.5tUS$123.8b24.2x48.3x2.4x
Price to Earnings Ratio

48.3x


Total Market Cap: US$6.0tTotal Earnings: US$123.8bTotal Revenue: US$2.5tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 48.5x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market2.97%
Healthcare1.38%
Healthcare Services7.30%
Life Sciences2.37%
Medical Equipment1.62%
Biotech0.56%
Pharma-0.51%
Healthtech-2.62%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.6x.
    • Analysts are expecting annual earnings growth of 16.0%, which is higher than its past year's earnings growth of 7.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 50% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
UNH UnitedHealth GroupUS$305.9811.7%
+US$29.0b		-47.1%PE23x
CVS CVS HealthUS$78.798.7%
+US$8.8b		12.3%PE57.1x
HCA HCA HealthcareUS$505.126.4%
+US$6.8b		49.2%PE16.6x
MRK MerckUS$123.181.9%
+US$5.8b		50.4%PE16.7x
ELV Elevance HealthUS$318.236.6%
+US$4.3b		-27.0%PE12.3x

Latest News

AMGN
US$349.81
Amgen
7D
-1.0%
1Y
20.2%
LLY
US$953.30
Eli Lilly
7D
-0.1%
1Y
26.5%

3 Reasons To Buy Eli Lilly Now

Apr 08
CVS
US$78.79
CVS Health
7D
8.7%
1Y
12.3%

CVS Health: A Diversified Income Play With Improving MA Rate Visibility For 2027

Apr 08
ABBV
US$211.59
AbbVie
7D
-1.6%
1Y
17.7%

ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution

Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.
INSM
US$160.18
Insmed
7D
-2.8%
1Y
137.1%
JNJ
US$241.30
Johnson & Johnson
7D
-1.2%
1Y
59.8%
ELV
US$318.23
Elevance Health
7D
6.6%
1Y
-27.0%

Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good

Apr 07
BMY
US$59.20
Bristol-Myers Squibb
7D
-4.1%
1Y
10.2%
SYK
US$340.01
Stryker
7D
3.2%
1Y
-6.3%

SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside

The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.
DHR
US$196.19
Danaher
7D
2.8%
1Y
2.2%

Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors

Apr 06
UNH
US$305.98
UnitedHealth Group
7D
11.7%
1Y
-47.1%

UnitedHealth: Why It's Still Not Too Late To Buy The Turnaround

Apr 05
MDT
US$88.65
Medtronic
7D
3.0%
1Y
4.0%

MDT: New Product Launches And 2027 Outlook Will Drive Re Rating Potential

The updated analyst price target for Medtronic has been revised slightly lower to $110.60. Analysts generally trimmed expectations for revenue growth and applied a slightly higher discount rate, partially offset by modestly higher profit margin assumptions and a similar future P/E framework.
PFE
US$27.47
Pfizer
7D
-3.8%
1Y
22.1%

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
MRK
US$123.18
Merck
7D
1.9%
1Y
50.4%

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.
RGC
US$28.88
Regencell Bioscience Holdings
7D
-14.4%
1Y
3,595.1%
HCA
US$505.12
HCA Healthcare
7D
6.4%
1Y
49.2%

HCA: Future Upside Will Center On Georgia Medicaid SDP Earnings Support

HCA Healthcare's analyst price targets have moved higher by a broad range that stretches into the mid $600s, reflecting analysts' updated models around Georgia's newly approved $1.9b Medicaid SDP program and potential efficiency gains from AI that could influence valuation multiples. Analyst Commentary Recent Street research around HCA Healthcare centers on two themes that matter for valuation: the newly approved Georgia Medicaid SDP program and potential AI driven efficiency gains.